0000000000869349

AUTHOR

Lili Zhu

showing 2 related works from this author

LBA9_PR Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): F…

2020

Oncologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentCheckmateCancerHematologymedicine.diseaseGastroesophageal JunctionOncologyInternal medicinemedicineNivolumabbusinessAdjuvantAnnals of Oncology
researchProduct

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

2021

BackgroundNo adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer. MethodsWe conducted CheckMate 577, a global, randomized, double-blind, placebo-controlled phase 3 trial to evaluate a checkpoint inhibitor as adjuvant therapy in patients with esophageal or gastroesophageal junction cancer. Adults with resected (R0) stage II or III esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy and had residual pathological disease were randomly assigned in a 2:1 ratio to receive nivolumab (at a dose of 240 mg every 2 weeks fo…

AdultMalemedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatment[SDV.CAN]Life Sciences [q-bio]/CancerKaplan-Meier EstimateAdenocarcinoma030204 cardiovascular system & hematologyGastroenterologyB7-H1 AntigenDisease-Free Survival03 medical and health sciences0302 clinical medicineDouble-Blind MethodStomach NeoplasmsInternal medicineMedicine and Health SciencesmedicineCarcinomaHumans030212 general & internal medicineEsophagusImmune Checkpoint InhibitorsNeoadjuvant therapyAgedAged 80 and overChemotherapybusiness.industryCancerChemoradiotherapy AdjuvantGeneral MedicineMiddle Agedmedicine.diseaseNeoadjuvant TherapyIntention to Treat Analysis3. Good healthNivolumabmedicine.anatomical_structureChemotherapy AdjuvantCarcinoma Squamous CellFemaleEsophagogastric JunctionNivolumabbusinessAdjuvantChemoradiotherapyNew England Journal of Medicine
researchProduct